Abstract
“Insulin at 100” joins a body of new scholarship being produced globally to commemorate the discovery of insulin. This paper brings to light a new perspective on the collaboration between two North American institutions: the University of Toronto in Canada and Eli Lilly & Company in the United States. It focuses on the collaboration’s complexities, actors who have not been examined previously, and implications for both parties and the general public. The article contributes to existing scholarship by expanding the collaboration story to include central actors at both Eli Lilly and the University of Toronto in a continuous and collaborative cycle of discovery and innovation.
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.